In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae.

Eravacycline has been shown to have broad-spectrum activity against Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae (CRE). We compared the activity of eravacycline with that of tigecycline in CRE isolates cultured from patients at an academic medical centre. Eravacycline was more potent than tigecycline [mean minimum inhibitory concentration (MIC) ratio = 0.

In vitro activity of plazomicin compared to other clinically relevant aminoglycosides in carbapenem-resistant Enterobacteriaceae.

We evaluated the in vitro activity of plazomicin against other aminoglycosides in 122 clinical carbapenem-resistant Enterobacteriaceae isolates using several clinical susceptibility breakpoints. Plazomicin had excellent in vitro activity with 98% overall susceptibility. Amikacin was the next most active with 86% overall susceptibility.

Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center.

Background: Carbapenem-resistant Enterobacteriaceae (CRE) cause significant mortality and are resistant to most antimicrobial agents. Imipenem/relebactam, a novel beta-lactam/beta-lactamase inhibitor combination, and 16 other antimicrobials were evaluated against non-metallo-beta-lactamase-producing carbapenem-resistant Enterobacteriaceae clinical isolates from a United States tertiary academic medical center.

Objectives: To evaluate imipenem/relebactam and other commonly utilised antimicrobial agents against carbapenem-resistant Enterobacteriaceae.

Evaluation of the BD Phoenix automated system for determining antimicrobial susceptibility against carbapenem-resistant Enterobacteriaceae compared with broth microdilution.

Purpose: Carbapenem-resistant Enterobacteriaceae (CRE) are increasingly widespread in the healthcare system, resulting in infections associated with mortality of up to 50%. Many laboratories use automated systems to identify CRE isolates and determine susceptibility. The aim of this study was to evaluate categorical agreement between the BD Phoenix automated system and the gold standard - broth microdilution - in determining minimum inhibitory concentrations of CRE.

Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin.

Amikacin is administered with a carbapenem to treat serious infections caused by carbapenem-resistant Enterobacteriaceae (CRE). The varying degrees of activity of the individual agents correspond to differences in activity of the 2 in combination. Amikacin and meropenem are not bactericidal against amikacin-resistant CRE.

Staggering the administration of polymyxin B and meropenem in time-kill against carbapenem-resistant Enterobacteriaceae exhibiting a wide range of meropenem MICs.

Little is known regarding the appropriate timing and sequencing of a carbapenem and polymyxin in combination against carbapenem-resistant Enterobacteriaceae. Meropenem and polymyxin B were administered simultaneously or 1 agent 2 h prior to the other, in vitro. The carbapenem should be administered prior to the polymyxin when used in combination.

Effect of increasing meropenem MIC on the killing activity of meropenem in combination with amikacin or polymyxin B against MBL- and KPC-producing Enterobacter cloacae.

Carbapenem resistant Enterobacteriaceae (CRE) are a growing threat worldwide. Infections caused by these organisms have exhibited high rates of mortality (50%) for which there is no standard of care and a dearth of clinical trials. Most in vitro data on CRE focus on Klebsiella pneumoniae, but it is known that effective therapy may depend on species or even strain.

Comparison of sensory neuron growth cone and filopodial responses to structurally diverse aggrecan variants, in vitro.

Following spinal cord injury, a regenerating neurite encounters a glial scar enriched in chondroitin sulfate proteoglycans (CSPGs), which presents a major barrier. There are two points at which a neurite makes contact with glial scar CSPGs: initially, filopodia surrounding the growth cone extend and make contact with CSPGs, then the peripheral domain of the entire growth cone makes CSPG contact. Aggrecan is a CSPG commonly used to model the effect CSPGs have on elongating or regenerating neurites.